Amer Sports Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach co...
Latest News
12 days ago · zacks.com
ASO vs. AS: Which Stock Is the Better Value Option?Investors interested in stocks from the Leisure and Recreation Products sector have probably already heard of Academy Sports and Outdoors, Inc. (ASO) and Amer Sports, Inc. (AS). But which of these two companies is the best option for those looking for undervalued stocks?
16 days ago · gurufocus.com
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
21 days ago · fool.com
Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?The disposition involved ~117,000 shares for a total value of $3.1 million. Traded shares represented 78% of the equity stake held directly before the filing.
22 days ago · gurufocus.com
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseNew SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
1 month ago · gurufocus.com
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
1 month ago · gurufocus.com
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisAbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
2 months ago · seekingalpha.com
Amer Sports, Inc. (AS) Analyst/Investor Day TranscriptAmer Sports, Inc. (AS) Analyst/Investor Day Transcript
2 months ago · fool.com
Amer Sports' 2026 Outlook: Margin Expansion Drives Growth as Direct-to-Consumer Model ScalesAmer Sports demonstrates strong growth through its premium Arc'teryx and Salomon brand platforms. The company faces significant risks from trade policy volatility and potential tariff impacts.
2 months ago · seekingalpha.com
Amer Sports: Best-In-Class With Undeniable MomentumAmer Sports stands out with best-in-class revenue growth and a synergistic, diversified brand portfolio. Despite a ~30% YTD decline, AS trades at valuation multiples slightly below the S&P 500, creating an attractive entry point. AS maintains gross margins near 60% and a net cash position, supporting scalability and financial resilience.
2 months ago · businesswire.com
Amer Sports Updates Long-Term Financial Algorithm and Third Quarter 2026 GuidanceNEW YORK--(BUSINESS WIRE)--Amer Sports, Inc. (NYSE:AS) (“Amer Sports” or the “Company”) will host an Investor Day tomorrow beginning 3:00 am Eastern Time, which will be webcast live from Annecy, France (details below). In conjunction with this meeting, the Company is updating its long-term financial algorithm and financial guidance for the third quarter of 2026. CEO James Zheng commented "Our unique portfolio of premium sports & outdoor brands continues to deliver great financial results in.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AS